Literature DB >> 8907280

Primary extranodal non-Hodgkin's lymphoma in adults: clinicopathological and survival characteristics.

T Economopoulos1, N Asprou, N Stathakis, E Papageorgiou, J Dervenoulas, K Xanthaki, S Raptis.   

Abstract

Among 318 cases of non-Hodgkin's lymphoma (NHL) treated in our unit, 145 (45.6%) had primary extranodal NHL (PE-NHL). The stomach was the most common site (42.1%), followed by the PE-NHL of the head and neck region. Histologically aggressive histologies (65.5% intermediate and 20.7% high grade) predominated. 89.6% of the cases were localized (stage IE, 51% and stage II, 38.6%) but 28% had B symptoms. CR was achieved in 82.1% of the cases. 5-years disease free survival and overall survival were both 65%. Factors that influence prognosis were stage and high grade histology. Among various primary sites the Waldeyer's ring, small intestine and testes had the worse prognosis. Compared to nodal NHL, the PE-NHL were more frequently localized, belonged more often to aggressive histologies and had more often distal extranodal relapses. CR rates and disease free and overall survival were significantly better for PE-NHL. The survival rates, however, listed according to stage and histology for nodal and PE-NHL were not different. We conclude that although PE-NHL differed from nodal NHL in several respects, prognosis is mainly a factor of stage and histology rather than of the primary localization per se.

Entities:  

Mesh:

Year:  1996        PMID: 8907280     DOI: 10.3109/10428199609067590

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  8 in total

1.  Extensive Extranodal Involvement of Rare Sites in Non Hodgkin's Lymphoma Detected on (18)F- FDG PET-CT: A Case Report.

Authors:  Varun Singh Dhull; Punit Sharma; Suhas Singla; Nauroze Asghar Faizi; Sanjay Thulkar; Chandersekhar Bal; Rakesh Kumar
Journal:  Nucl Med Mol Imaging       Date:  2012-11-09

2.  Differentiation of single lymphoma primary cells and normal B-cells based on their adhesion to mesenchymal stromal cells in optical tweezers.

Authors:  Kamila Duś-Szachniewicz; Sławomir Drobczyński; Marta Woźniak; Krzysztof Zduniak; Katarzyna Ostasiewicz; Piotr Ziółkowski; Aleksandra K Korzeniewska; Anil K Agrawal; Paweł Kołodziej; Kinga Walaszek; Zbigniew Bystydzieński; Grzegorz Rymkiewicz
Journal:  Sci Rep       Date:  2019-07-08       Impact factor: 4.379

3.  Hematological Evaluation of Primary Extra Nodal Versus Nodal NHL: A Study from North India.

Authors:  Prateek Bhatia; Reena Das; Jasmina Ahluwalia; Pankaj Malhotra; Neelam Varma; Subhash Varma; Amita Trehan; Ram Kumar Marwaha
Journal:  Indian J Hematol Blood Transfus       Date:  2011-05-08       Impact factor: 0.900

Review 4.  Colorectal Lymphoma: A Review.

Authors:  Nathan D Gay; Andy Chen; Craig Y Okada
Journal:  Clin Colon Rectal Surg       Date:  2018-09-04

5.  Gastrointestinal tract metastasis of mandibular diffuse large B-cell lymphoma.

Authors:  Turker Yucesoy; Erdem Kilic; Hakan Ocak; Alper Alkan; Kemal Deniz
Journal:  Clin Case Rep       Date:  2018-07-10

6.  Survival and Epidemiologic Trends of Lymphomas in Saudi Arabia: A 10-Year Report from a Tertiary Care Hospital.

Authors:  Mashael Yahya Altowairqi; Mohammed Yousef Alyousef; Mohammed Khaled Ghandour; Abdulrahman Abdulmohsen Alrashed; Yousef Jebrin Aljebrin; Ghadah Abdulkarim Alotheem; Aamer Aleem; Farjah Algahtani; Musa F Alzahrani
Journal:  Saudi J Med Med Sci       Date:  2022-01-12

7.  Analysis and prediction of relative survival trends in patients with non-Hodgkin lymphoma in the United States using a model-based period analysis method.

Authors:  Shuping Xie; Zhong Yu; Aozi Feng; Shuai Zheng; Yunmei Li; You Zeng; Jun Lyu
Journal:  Front Oncol       Date:  2022-09-27       Impact factor: 5.738

8.  Primary extra-nodal diffuse large B-cell lymphoma: A prognostic analysis of 141 patients.

Authors:  Haorui Shen; Zhang Wei; Daobin Zhou; Yan Zhang; Xiao Han; Wei Wang; Lu Zhang; Chen Yang; Jun Feng
Journal:  Oncol Lett       Date:  2018-05-24       Impact factor: 2.967

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.